Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase NA 1Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Other hematologic neoplasm 1NET 1Lymphoid 1Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 2Fluorouracil 2Everolimus 2trametinib 1toripalimab 1fosbretabulin 1fluorocholine 1dabrafenib 1combretastatin 1cobimetinib 1anlotinib 1Water 1Vemurafenib 1Testosterone 1Temozolomide 1Somatostatin 1Sodium Iodide 1Sodium Chloride 1Sirolimus 1Radiotherapy 1Radiofrequency Ablation 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1PE regimen 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Injections 1Erythromycin 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Positron Emission Tomography Computed Tomography × Endocrine × Clear all
NCT04552847 2022-02-17

Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors

Universitaire Ziekenhuizen KU Leuven

Phase 2/3 Completed
85 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡